Why the study?
Does cardiac magnetic resonance imaging identify late gadolinium enhancement in breast cancer patients with trastuzumab-induced cardiomyopathy?
Does cardiac magnetic resonance imaging identify late gadolinium enhancement in breast cancer patients with trastuzumab-induced cardiomyopathy?
LGE-CMR consistently detects subepicardial linear late gadolinium enhancement in patients with trastuzumab-induced cardiomyopathy, highlighting its potential utility for early detection of cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
May support LGE-CMR for trastuzumab cardiotoxicity detection; leaves open prospective validation before clinical use.
Fallah‐Rad et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: